



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Cetuximab (powder)

Cat. No.:	HY-P9905A
CAS No.:	205923-56-4
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Cetuximab powder (C225 powder) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a K_d of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity ^[1] .
In Vitro	<p>Cetuximab powder (C225 powder) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a K_d of 0.201 nM for soluble EGFR by SPR. Cetuximab powder also exhibits a K_d of 0.147 nM for EGFR in fixed A431 cells by ELISA^[1].</p> <p>Cetuximab powder (C225; 30 nM) time-dependently inhibits the proliferation of SCC-1, SCC-11B, SCC-38, and SCC-13Y cells after treatment for 8 d. Cetuximab powder (30 nM) causes G_0/G_1 arrest, induces apoptosis, and reduces Rb, p27^{KIP1}, Bcl-2, and Bax expression in SCC-13Y cells. Cetuximab powder (30 nM) also enhances radiosensitivity and increases radiation-induced apoptosis in SCC-13Y cells^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
In Vivo	<p>Cetuximab powder (C225 powder) (1 mg/injection) has effect on the tumour volume but the effect is more pronounced on UT-SCC-14 xenografts. In UT-SCC-14 xenografts, Cetuximab significantly reduces the expression of EGFR, pEGFR and Ki67. Cetuximab powder significantly decreases the expression in the MCT1 and GLUT1 cells but differences are more pronounced in UT-SCC-14 xenografts^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

CUSTOMER VALIDATION

- Cell. 2023 Dec 7;186(25):5606-5619.e24.
- Cell Res. 2022 Oct 14.
- Cell Res. 2020 Dec;30(12):1063-1077.
- Mol Cancer. 2021 Jan 18;20(1):17.
- Am J Respir Crit Care Med. 2022 Jul 11.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Goldstein NI, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995 Nov;1(11):1311-8.

[2]. Gustafsson H, et al. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model. Cell Biochem Biophys. 2017 Jul 29.

[3]. Huang SM, et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999 Apr 15;59(8):1935-40.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA